---
title: "Wall Street Analysts Think Passage Bio  ( PASG )  Could Surge 731%: Read This Before Placing a Bet"
description: "The mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analy"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255500187.md"
published_at: "2025-09-01T16:03:59.000Z"
---

# Wall Street Analysts Think Passage Bio  ( PASG )  Could Surge 731%: Read This Before Placing a Bet

> The mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

### Related Stocks

- [PASG.US - Passage Bio](https://longbridge.com/en/quote/PASG.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Assessing Bio-Rad (BIO) Valuation After Recent Share Price Weakness And Longer-Term Return Pressures | Bio-Rad Laboratories (BIO) has experienced significant share price declines, prompting a reassessment of its valuation.  | [Link](https://longbridge.com/en/news/275997412.md) |
| Weston Nichols Reports Acquisition of Common Shares of Passage Bio Inc | Lynx1 Capital Management LP, along with Weston Nichols and other beneficial owners, has reported the acquisition of comm | [Link](https://longbridge.com/en/news/257440258.md) |
| XBI vs. IBB: Which Biotech ETF do Analysts Prefer in 2026? | In 2026, Biotech ETFs, particularly the SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB), are gaining atte | [Link](https://longbridge.com/en/news/276158809.md) |
| Aqua Bio Technology adjusts ownership structure after NOK 10m private placement | Aqua Bio Technology ASA has completed a private placement of 2,000,000 new shares at NOK 5.00 each, coinciding with a pl | [Link](https://longbridge.com/en/news/276015231.md) |
| Climb Bio Director Thomas Stephen Basil Reports Disposal of Common Shares | Thomas Stephen Basil, Director of Climb Bio Inc., has reported the disposal of common shares of the company. The full fi | [Link](https://longbridge.com/en/news/276167346.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.